Literature DB >> 10942479

Estrogen replacement in perimenopause-related depression: a preliminary report.

P J Schmidt1, L Nieman, M A Danaceau, M B Tobin, C A Roca, J H Murphy, D R Rubinow.   

Abstract

OBJECTIVES: We examined the efficacy of estrogen in the treatment of depression in perimenopausal women with and without hot flushes. STUDY
DESIGN: Women with perimenopause-related depression were randomized in a double-blind parallel design to receive either 17beta-estradiol or placebo for 3 weeks. Subsequently, women receiving estradiol during the first 3 weeks continued receiving estradiol for an additional 3 weeks, whereas women who had received placebo crossed over to estradiol for 3 weeks. Outcome measures included standardized mood rating scales and a visual analog scale self-report instrument.
RESULTS: Of 34 female subjects, 16 received estradiol first and 18 received placebo first. After 3 weeks of estradiol, standardized mood rating scale scores and visual analog scale symptom scores (eg, sadness, anhedonia, and social isolation) were significantly decreased compared with baseline scores (P <.01) and were significantly lower than scores in women receiving placebo (P <.01), who showed no significant improvement. Neither the presence of hot flushes nor the duration of treatment (3 weeks vs 6 weeks) influenced outcome. A full or partial therapeutic response was seen in 80% of subjects receiving estradiol and 22% of those receiving placebo.
CONCLUSION: In this preliminary study estradiol replacement effectively treats perimenopausal depression independent of its salutary effects on vasomotor symptoms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942479     DOI: 10.1067/mob.2000.106004

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  134 in total

1.  Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN).

Authors:  Joyce T Bromberger; Laura L Schott; Howard M Kravitz; Maryfran Sowers; Nancy E Avis; Ellen B Gold; John F Randolph; Karen A Matthews
Journal:  Arch Gen Psychiatry       Date:  2010-06

2.  Gender differences in antidepressant response.

Authors:  Prakash S Masand
Journal:  Curr Psychiatry Rep       Date:  2003-07       Impact factor: 5.285

3.  Estrogen treatment impairs cognitive performance after psychosocial stress and monoamine depletion in postmenopausal women.

Authors:  Paul A Newhouse; Julie Dumas; Heather Wilkins; Emily Coderre; Cynthia K Sites; Magdalena Naylor; Chawki Benkelfat; Simon N Young
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

Review 4.  Effects of hormone therapy on cognition and mood.

Authors:  Barbara Fischer; Carey Gleason; Sanjay Asthana
Journal:  Fertil Steril       Date:  2014-04       Impact factor: 7.329

Review 5.  Bipolar Disorder in the Menopausal Transition.

Authors:  Dawn Truong; Wendy Marsh
Journal:  Curr Psychiatry Rep       Date:  2019-11-25       Impact factor: 5.285

6.  Neurobiological Underpinnings of the Estrogen - Mood Relationship.

Authors:  Whitney Wharton; Carey E Gleason; Sandra R M S Olson; Cynthia M Carlsson; Sanjay Asthana
Journal:  Curr Psychiatry Rev       Date:  2012-08-01

Review 7.  Menopausal Symptoms and Their Management.

Authors:  Nanette Santoro; C Neill Epperson; Sarah B Mathews
Journal:  Endocrinol Metab Clin North Am       Date:  2015-09       Impact factor: 4.741

8.  Estrogen-mediated effects on depression and memory formation in females.

Authors:  Tracey J Shors; Benedetta Leuner
Journal:  J Affect Disord       Date:  2003-03       Impact factor: 4.839

Review 9.  Role of estrogen in the aetiology and treatment of mood disorders.

Authors:  U Halbreich; L S Kahn
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 10.  Effect of reproductive hormones and selective estrogen receptor modulators on mood during menopause.

Authors:  Claudio N Soares; Jennifer R Poitras; Jennifer Prouty
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.